Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00297414 · ClinicalTrials.gov registry record

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

A clinical trial of Mild Cognitive Impairment, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Completed
Registry status
1,083
Enrollment target
20
Study locations

NCT00297414 is a study of Mild Cognitive Impairment that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 1,083 participants, below the 1,265-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00297414, a study of Mild Cognitive Impairment, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

COMPLETED
Registry status
1,083 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to collect data of patients who were randomized (assignment of study medication by chance) and treated in 3 previous studies of galantamine (CR003145, CR002014 and CR005947) for the treatment of mild cognitive impairment (isolated memory impairment). This data were not recorded during the course of these 3 previous studies.

Conditions Studied

Mild Cognitive Impairment

Interventions

  • OTHER No intervention

Study Locations (20)

California

  • - Laguna Woods
  • - Northridge
  • - Oceanside
  • - Paramount
  • - San Diego
  • - San Francisco

Florida

  • - Fort Lauderdale
  • - Miami
  • - North Miami
  • - Oscala F
  • - St. Petersburg
  • - West Palm Beach

Connecticut

  • - Hamden
  • - Hartford
  • - New Haven

Arizona

  • - Tucson

Georgia

  • - Atlanta

Illinois

  • - Chicago

Kentucky

  • - Paducah

Maryland

  • - Glen Burnie

Trial Details

FieldValue
Enrollment Target 1,083 participants
Start Date 2004-06
Est. Completion 2005-01

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

102 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00297414

The ClinicalTrials.gov registry entry for NCT00297414 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,083 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,265-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (14% lower). The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.

NCT00297414 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00297414 about?

NCT00297414 is a clinical study titled "An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine". The purpose of the study is to collect data of patients who were randomized (assignment of study medication by chance) and treated in 3 previous studies of galantamine (CR003145, CR002014 and CR005947) for the treatment of mild cognitive impairment (isolated memory impairment). This data were not re...

What is the current status of trial NCT00297414?

This trial is currently completed. The enrollment target is 1,083 participants. The study started on 2004-06. Estimated completion is 2005-01.

What conditions does trial NCT00297414 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT00297414?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT00297414?

This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00297414 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mild Cognitive Impairment

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.